Highlights
Postmarketing surveillance identified a hepatic adverse event reporting signal for fezolinetant after U.S. approval, with the strongest disproportionality seen for alanine aminotransferase, aspartate aminotransferase, and liver function test elevations.
The signal was driven more by laboratory abnormalities than by consistently reported severe clinical liver outcomes such as overt hepatic failure.
